Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290042 | 1.00 | CA2 (0.41) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL6269225 | 1.00 | CA2 (0.41) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL7148753 | 1.00 | CA2 (0.41) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL6241033 | 1.00 | CA2 (0.41) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL13800900 | 1.00 | CA2 (0.41) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL9226594 | 0.91 | HPGD (0.42) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL27174712 | 0.90 | CA2 (0.35) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL8819275 | 0.87 | ALDH1A1 (0.47) | CA2CA1CA9RXFP1ALDH1A1 | |
| SCHEMBL15828255 | 0.87 | CA2 (0.42) | CA2CA1CA9HPGDCYP3A4 | |
| SCHEMBL7767515 | 0.86 | HPGD (0.43) | CA2CA1CA9HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241556-A1 | METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD | Coll Farma S.L. (ES) | 2010-10-20 | — | — | EP | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2022074391-A1 | COMPOUNDS INHIBITORS OF METTL3 | STORM THERAPEUTICS LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-8053217-B2 | Method for producing eritadenine in liquid phase fermentation | WORKING BUGS AB (SE) | 2011-11-08 | — | — | US | disclosed |
| EP-2241556-A1 | METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD | Coll Farma S.L. (ES) | 2010-10-20 | — | — | EP | disclosed |
| US-20100221794-A1 | A NEW METHOD FOR PRODUCING ERITADENINE IN LIQUID PHASE FERMENTATION | Working Bugs AB c/o Kris a. Berglund (SE) | 2010-09-02 | — | — | US | disclosed |
| EP-2147112-A1 | A NEW METHOD FOR PRODUCING ERITADENINE IN LIQUID PHASE FERMENTATION | Working Bugs AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | CEQUENT PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-5366954-A | Bathing in storage solution to extend bloom life | EPITOPE, INC. (US) | 1994-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | TYMP, DPYD, TYMS | CA2 4386/4885CA1 4221/4885CA9 4108/4885 |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CA2 2974/4885CA1 4418/4885CA9 1767/4885 |
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CA2 2833/4885CA1 4326/4885CA9 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.